secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001689375-23-000053
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Q2 cash $376.8M; on track to dose first participant in ENTR-601-44 Phase 1 in Sept 2023
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $376.8M as of June 30, 2023, up from $188.7M at year-end 2022; cash runway extended through 2025.
- Collaboration revenue of $18.2M in Q2 2023 (none in prior year); net loss $25.9M vs $23.2M.
- Received MHRA and REC authorization for Phase 1 trial of ENTR-601-44 in healthy volunteers in UK; first dosing expected in September 2023 with data in H2 2024.
- IND for ENTR-601-44 on clinical hold with FDA; update expected in Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937523000053/0001689375-23-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937523000053/trda-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001689375-23-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer